Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
All-trans retinoic acid + clobetasol propionate is a topical combination therapy used primarily for the treatment of psoriasis vulgaris and other corticosteroid-responsive dermatoses. All-trans retinoic acid (tretinoin) is a derivative of vitamin A that modulates gene expression by activating retinoic acid receptors, promoting cell differentiation and reducing hyperproliferation of keratinocytes. Clobetasol propionate is a highly potent synthetic corticosteroid that acts as an agonist at glucocorticoid receptors, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects. The combination has demonstrated efficacy in improving erythema, infiltration, scaling of skin lesions, and overall PASI scores in patients with mild-to-moderate psoriasis vulgaris[5]. This fixed-dose compound ointment has shown similar or superior efficacy compared to other standard topical therapies such as calcipotriol/betamethasone dipropionate ointment[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on All-trans retinoic acid + clobetasol propionate.